1.
Indirect medical costs (travel costs).
2.
Total reported units of healthcare utilization and total reported days of absenteeism and presenteeism in the ACT-group and CBT-group at over assessments.
Mean and median incremental costs and effects of the 2,500 bootstraps.
CONSORT 2010 checklist of information to include when reporting a randomised trial.
Cost-effectiveness planes of the sensitivity analyses.
Flowchart of study participants.
Cost-effectiveness plane reflecting the probability that blended ACT is cost-effective compared to CBT in terms of treatment responders.
Cost-effectiveness plane reflecting the probability that blended ACT is cost-effective compared to CBT in terms of QALYs (cost-utility).
Acceptability curve reflecting the probability that blended ACT is cost-effective compared to CBT in terms of QALYs (cost-utility) at different willingness-to-pay ceilings.
Baseline characteristics of study sample.